PH12022551110A1 - Methods of treating depressive disorders - Google Patents

Methods of treating depressive disorders

Info

Publication number
PH12022551110A1
PH12022551110A1 PH1/2022/551110A PH12022551110A PH12022551110A1 PH 12022551110 A1 PH12022551110 A1 PH 12022551110A1 PH 12022551110 A PH12022551110 A PH 12022551110A PH 12022551110 A1 PH12022551110 A1 PH 12022551110A1
Authority
PH
Philippines
Prior art keywords
methods
depressive disorders
treating depressive
human
compound
Prior art date
Application number
PH1/2022/551110A
Other languages
English (en)
Inventor
Gregory N Beatch
Cynthia Louise Harden
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of PH12022551110A1 publication Critical patent/PH12022551110A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH1/2022/551110A 2019-11-08 2020-11-06 Methods of treating depressive disorders PH12022551110A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962932724P 2019-11-08 2019-11-08
PCT/US2020/059481 WO2021092439A1 (en) 2019-11-08 2020-11-06 Methods of treating depressive disorders

Publications (1)

Publication Number Publication Date
PH12022551110A1 true PH12022551110A1 (en) 2024-02-26

Family

ID=73643360

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/551110A PH12022551110A1 (en) 2019-11-08 2020-11-06 Methods of treating depressive disorders

Country Status (19)

Country Link
US (2) US12178811B2 (https=)
EP (1) EP4054580A1 (https=)
JP (2) JP2022553569A (https=)
KR (1) KR20220098746A (https=)
CN (1) CN114667146A (https=)
AU (1) AU2020380961A1 (https=)
BR (1) BR112022008580A2 (https=)
CA (1) CA3155812A1 (https=)
CL (1) CL2022001102A1 (https=)
CO (1) CO2022008001A2 (https=)
CR (1) CR20220250A (https=)
GE (2) GEP20257732B (https=)
IL (1) IL292678A (https=)
MA (1) MA56607A1 (https=)
MX (1) MX2022005490A (https=)
PE (1) PE20221766A1 (https=)
PH (1) PH12022551110A1 (https=)
TW (1) TW202128162A (https=)
WO (1) WO2021092439A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005490A (es) 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.
CA3159876A1 (en) 2019-12-06 2021-06-10 James MURROUGH Method of treatment with kcnq channel openers
US11957675B2 (en) 2021-02-09 2024-04-16 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia
US20220288057A1 (en) * 2021-02-09 2022-09-15 Xenon Pharmaceuticals Inc. Conjoint therapy for treating seizure disorders
US20250128055A1 (en) * 2021-10-08 2025-04-24 Albert Ludwigs Universität Freiburg Treatment of psychiatric disorders with deep brain stimulation

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639385A (en) 1968-07-26 1972-02-01 Eastman Kodak Co Heterocyclic monoazo compounds from n n-diaralkyl anilines and polyester textile materials dyed therewith
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4181803A (en) 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
ATE25078T1 (de) 1982-10-27 1987-02-15 Degussa 2-amino-3-acylamino-6-benzylamino-pyridinderivate mit anti-epileptischer wirkung.
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
EP0193056B1 (de) 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
JP2583067B2 (ja) 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (https=) 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5428039A (en) 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
JP4097285B2 (ja) 1994-09-22 2008-06-11 リチャード・アラン・スミス 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
US5679706A (en) 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
WO1996019233A2 (en) 1994-12-12 1996-06-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
AU8561298A (en) 1997-08-08 1999-03-01 Chugai Seiyaku Kabushiki Kaisha Remedies for complications of diabetes
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
BR9916162A (pt) 1998-12-14 2001-09-04 Cellegy Pharma Inc Composição e método para o tratamento de um distúrbio anorretal e para controlar a dor associada com o mesmo
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU766648B2 (en) 1999-03-17 2003-10-23 Axys Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
PT1200073E (pt) 1999-07-06 2007-03-30 Lilly Co Eli Antagonistas selectivos do receptor de iglur5 para o tratamento de enxaqueca
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
ATE380176T1 (de) 1999-08-04 2007-12-15 Icagen Inc Benzanilide als öffner des kaliumkanals
EP1200086A4 (en) 1999-08-04 2009-05-27 Icagen Inc THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
US20020183395A1 (en) 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2003068769A1 (en) 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
WO2003097586A1 (en) 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
WO2003106454A1 (en) 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd 1h-isoquinoline-oxazolidinone derivaties and their use as antibacterial agents
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7045551B2 (en) 2002-11-22 2006-05-16 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
ATE488231T1 (de) 2002-12-23 2010-12-15 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
ES2282701T3 (es) 2002-12-27 2007-10-16 H. Lundbeck A/S Derivados de 1,2,4-triaminobenceno utiles para tratar trastornos del sistema nervioso central.
EP1606247A1 (en) 2003-03-14 2005-12-21 H. Lundbeck A/S Substituted aniline derivatives
WO2004082677A1 (en) 2003-03-21 2004-09-30 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
MXPA05010174A (es) 2003-04-25 2005-11-08 Lundbeck & Co As H Derivados de indol e indolina sustituidos.
WO2004105795A1 (en) 2003-05-27 2004-12-09 Altana Pharma Ag Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
AU2005233642A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyridines as potassium ion channel modulators
RU2006139930A (ru) 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
CA2589001A1 (en) 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for neuropathic pain
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP1861394A1 (en) 2005-03-03 2007-12-05 H.Lundbeck A/S Substituted pyridine derivatives
AU2006252519B2 (en) 2005-06-02 2012-08-30 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
US7683058B2 (en) 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
WO2007128462A1 (en) 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
SG174095A1 (en) * 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
CN101578259A (zh) 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
US20090018154A1 (en) 2007-05-17 2009-01-15 Endo Pharmaceuticals, Inc., A Corporation Of Delaware Opioid and methods of making and using the same
AR070513A1 (es) * 2007-08-01 2010-04-14 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
JP2011506391A (ja) * 2007-12-11 2011-03-03 ノイロサーチ アクティーゼルスカブ カリウムチャネル活性化因子として有用な、新規の２−エチル−メチル−アミノ−３−アミド−６−アミノ−ピリジン誘導体
US20100323016A1 (en) 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
JP2013517315A (ja) 2010-01-20 2013-05-16 グラクソ グループ リミテッド 新規組成物
WO2013067591A1 (en) 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
EP4241843B1 (en) * 2018-02-20 2025-05-21 H. Lundbeck A/S Alcohol derivatives as kv7 potassium channel openers
WO2019217924A1 (en) 2018-05-11 2019-11-14 Xenon Pharmaceuticals Inc. Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
MX2022005490A (es) 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.
CA3159876A1 (en) 2019-12-06 2021-06-10 James MURROUGH Method of treatment with kcnq channel openers
US20210213009A1 (en) 2019-12-13 2021-07-15 Xenon Pharmaceuticals Inc. Methods of treating pain
US20220288057A1 (en) 2021-02-09 2022-09-15 Xenon Pharmaceuticals Inc. Conjoint therapy for treating seizure disorders
US11957675B2 (en) 2021-02-09 2024-04-16 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia
CA3151863C (en) 2021-10-27 2024-01-02 Shanghai Zhimeng Biopharma, Inc. Compound as potassium channel regulator and preparation and use thereof

Also Published As

Publication number Publication date
NZ787838A (en) 2025-08-29
WO2021092439A1 (en) 2021-05-14
MA56607A1 (fr) 2022-10-31
US20210161886A1 (en) 2021-06-03
GEP20257732B (en) 2025-02-10
CN114667146A (zh) 2022-06-24
CO2022008001A2 (es) 2022-06-10
US20250108044A1 (en) 2025-04-03
CA3155812A1 (en) 2021-05-14
KR20220098746A (ko) 2022-07-12
EP4054580A1 (en) 2022-09-14
TW202128162A (zh) 2021-08-01
CR20220250A (es) 2022-08-19
IL292678A (en) 2022-07-01
BR112022008580A2 (pt) 2022-08-09
PE20221766A1 (es) 2022-11-11
US12178811B2 (en) 2024-12-31
GEAP202415942A (en) 2024-10-28
JP2026001049A (ja) 2026-01-06
MX2022005490A (es) 2022-08-10
AU2020380961A1 (en) 2022-05-26
JP2022553569A (ja) 2022-12-23
CL2022001102A1 (es) 2023-01-27

Similar Documents

Publication Publication Date Title
PH12022551110A1 (en) Methods of treating depressive disorders
PH12020551898A1 (en) Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
JOP20220342A1 (ar) مركبات 2-أوكسو إيميدازوليدين -4- كربوكساميد كمثبطات لـ nav1.8
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
PH12019500025A1 (en) Cancer treatment combinations
GEAP202416348A (en) Methods and uses for treating anhedonia
MX2024014626A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton
BR112021021826A2 (pt) Terapias de combinação compreendendo os inibidores de apremilast e tyk2
RU2013123796A (ru) Способ лечения болезни дюпюитрена
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
BR112022010733A2 (pt) Métodos para tratar dor
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
GEAP202416349A (en) Conjoint therapy for treating seizure disorders
PH12021551839A1 (en) Crystal of diarylthiohydantoin compound
EP4364812A3 (en) Intranasal administration of ketamine to cluster headache patients
NZ787838B2 (en) Methods of treating depressive disorders
MY206505A (en) Therapeutic agent for glaucoma comprising fp agonist and -blocker
ZA202404183B (en) Treatment of major depressive disorder
NZ788497A (en) Use of reboxetine to treat nervous system disorders
MX2025001316A (es) Tratamiento de la urticaria con inhibidores de la cinasa de janus (jak)
MX2024015496A (es) Compuestos de pirimidina que contienen boro, composiciones que los contienen, metodos y usos de los mismos
EA202191938A1 (ru) Производные 2h-индазола в качестве терапевтических средств при видах рака головного мозга и метастазах в головной мозг
EA202091376A1 (ru) Нерацемические смеси и их применения